Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant TherapyRisha Nahar1,2*, Ishwar C Verma1, Roumi Deb2, Renu Saxena1, Parul Takkar3, Sujay Shad4, Rajiv Parakh5 and Prahlad K Sethi6
- *Corresponding Author:
- Risha Nahar
PhD Scholar, Center of Medical Genetics
Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi-110060, India
E-mail: [email protected]
Received date: May 06, 2013; Accepted date: June 24, 2013; Published date: June 26, 2013
Citation: Nahar R, Verma IC, Deb R, Saxena R, Takkar P, et al. (2013) Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant Therapy. Int J Genomic Med 1:101. doi:10.4172/2332-0672.1000101
Copyright: © 2013 Nahar R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aims: The present study focussed on deriving and validating a ‘genetic bleeding risk score’ (GBRS) based on genetic and non-genetic factors associated with bleeding in patients on long term anticoagulation therapy. Patients and Methods: Patients on warfarin (n=53) or acenocoumarol (n=257) long-term therapy were genotyped for twenty one SNPs in six genes. Two GBRSs were developed and validated. Results: The incidence rate was 16.86 and 4.46 per 100 person-years for minor and major bleeding respectively. The novel GBRS (positive predictive value = 83.3%, specificity = 97.4%) comprised of four parameters; age >65 years, F5 rs6025, VKORC1 rs9934438 and CYP2C9 rs1057911. Conclusions: The present study is the first to devise and validate a genetic based score for predicting bleeding among first time users of oral anticoagulants.